Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Health Protocols


  1. Clinic M. Heart Failure. 2017.
  2. Foley PM. Clinical Key. First Consult; Heart Failure. Available at: Accessed 7/19/2013. 2012.
  3. Hunt, S. A., Abraham, W. T., Chin, M. H., 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1–e90.
  4. Heidenreich, P. A., Albert, N. M., Allen, L. A., et al. Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association. Circ Heart Fail. 2013; 6(3):606-19.
  5. Brum PC, Bacurau AV, Medeiros A, Ferreira JC, Vanzelli AS, Negrao CE. Aerobic exercise training in heart failure: impact on sympathetic hyperactivity and cardiac and skeletal muscle function. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.]. Sep 2011;44(9):827-835.
  6. Iwanaga Y, Miyazaki S. Heart failure, chronic kidney disease, and biomarkers--an integrated viewpoint. Circulation journal: official journal of the Japanese Circulation Society. Jul 2010;74(7):1274-1282.
  7. Ferri FF. Ferri's Clinical Advisor. Heart Failure. Available at: Accessed 8/8/2013. 2013.
  8. CDC. Heart Failure Fact Sheet. 2019.
  9. Savarese G. Global Public Health Burden of Heart Failure. Cardiac failure review. 2017;3(1):7-11.
  10. Braunwald E. The war against heart failure: the Lancet lecture. The Lancet. 2015;385(9970):812-824.
  11. Mortensen SA. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2(6):641-649.
  12. Langsjoen PH, Langsjoen JO, Langsjoen AM, Lucas LA. Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. BioFactors. 2005;25(1-4):147-152.
  13. Langsjoen P, Littarru G, Silver M. Potential role of concomitant coenzyme Q~ 1~ 0 with statins for patients with hyperlipidemia. Current Topics in Nutraceutical Research. 2005;3(3):149.
  14. Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, Tamagawa H. Lovastatin decreases coenzyme Q levels in humans. Proceedings of the National Academy of Sciences of the United States of America. Nov 1990;87(22):8931-8934.
  15. Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. The American journal of cardiology. Nov 15 2004;94(10):1306-1310.
  16. Rubinstein J, Aloka F, Abela GS. Statin therapy decreases myocardial function as evaluated via strain imaging. Clin Cardiol. 2009;32(12):684-9.
  17. Marieb, E., and Hoehn, K. Human anatomy & physiology. 8 ed. San Francisco: Pearson Benjamin Cummings. 2010.
  18. Goldman, L. Schafer, A.L. Goldman's Cecil Medicine, Twenty-Fourth Edition. Heart Failure. Pathophysiology and Diagnosis. Available at: Accessed 7/10/2013.
  19. Association AH. Causes of Heart Failure. 2017.
  20. Mangini S, Pires PV, Braga FGM, Bacal F. Decompensated heart failure. Einstein (Sao Paulo, Brazil). 2013;11(3):383-391.
  21. Gazewood JD, Turner PL. Heart Failure with Preserved Ejection Fraction: Diagnosis and Management. American family physician. 2017;96(9):582-588.
  22. Inamdar AA, Inamdar AC. Heart Failure: Diagnosis, Management and Utilization. J Clin Med. 2016;5(7):62.
  23. American Heart Association. Ejection Fraction Heart Failure Measurement. Last reviewed 5/31/2017. Accessed 3/4/2019.
  24. Pazos-López P, Peteiro-Vázquez J, Carcía-Campos A, García-Bueno L, de Torres JPA, Castro-Beiras A. The causes, consequences, and treatment of left or right heart failure. Vascular health and risk management. 2011;7:237-254.
  25. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nature reviews. Cardiology. 2016;13(6):368-378.
  26. American Heart Association. Types of Heart Failure. Accessed 02/19/2019.
  27. NHLBI. What Is Heart Failure? - NHLBI, NIH. National Heart, Lung, and Blood Institute. 2012; Available at: [Accessed May 15, 2013].
  28. Hunt, S. A., Abraham, W. T., Chin, M. H., ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154–235.
  29. Abdel-Qadir, H. M., Lee, D.S. The contribution of familial and heritable risks in heart failure. Curr Opin Cardiol. 2007;22(3):214-9.
  30. Kenchaiah, S., Narula, J., and Vasan, R. S. Risk factors for heart failure. Med. Clin. North Am. 2004;88(5):1145–72.
  31. Dunn, S. P., Bleske, B., Dorsch, M., Macaulay, T., Van Tassell, B., and Vardeny, O. Nutrition and heart failure: impact of drug therapies and management strategies. Nutrition in Clinical Practice. 2009;24(1):60–75.
  32. Bryson, C. L., Mukamal, K. J., Mittleman, M. A.,  The Association of Alcohol Consumption and Incident Heart Failure. J Am Coll Cardiol. 2006;48(2):305–11.
  33. Suskin, N., Sheth, T., Negassa, A., Yusuf, S. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;37(6):1677-82.
  34. Conard, M.W., Haddock, C.K., Poston, W.S., Spertus, J.A., and the Cardiovascular Outcomes Research Consortium. The impact of smoking status on the health status of heart failure patients. Congest Heart Fail. 2009;15(2):82-6.
  35. Oerkild, B., Frederiksen, M., Hansen, J.F., Prescott, E. Self-reported physical inactivity predicts survival after hospitalization for heart disease. Eur J Cardiovasc Prev Rehabil. 2011;18(3):475-80.
  36. Djoussé L, Driver JA, Gaziano JM. Relation Between Modifiable Lifestyle Factors and Lifetime Risk of Heart Failure. JAMA. 2009;302(4):394-400.
  37. Yang Q. Added sugar intake and cardiovascular diseases mortality among us adults. JAMA Internal Medicine. 2014;174(4):516-524.
  38. Heist, E. K., and Ruskin, J. N. Atrial fibrillation and congestive heart failure: risk factors, mechanisms, and treatment. Prog Cardiovasc Dis. 2006;48(4):256–69.
  39. Britton, K.A., Gaziano, J.M., Djoussé, L. Normal systolic blood pressure and risk of heart failure in US male physicians. Eur J Heart Fail. 2009;11(12):1129-34.
  40. Kannel, W.B. Incidence and epidemiology of heart failure. Heart Fail Rev. 2000;5(2):167-73.
  41. Harinstein, M. E., Filippatos, G. S., and Gheorghiade, M. Acute heart failure syndromes: epidemiology, risk stratification and prognostic factors. Acute Card Care. 2009;11(2):77–82.
  42. Lehrke M, Marx N. Diabetes Mellitus and Heart Failure. The American journal of cardiology. 2017;120(1s):S37-s47.
  43. de Miguel Diez J, Morgan JC, Garcia RJ. The association between COPD and heart failure risk: a review. International journal of chronic obstructive pulmonary disease. 2013;8:305-312.
  44. Segall L, Nistor I, Covic A. Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review. J BioMed Research International. 2014;2014:21.
  45. Vestberg D, Rosengren A, Olsson M, Gudbjornsdottir S, Svensson AM, Lind M. Relationship Between Overweight and Obesity With Hospitalization for Heart Failure in 20,985 Patients With Type 1 Diabetes: A population-based study from the Swedish National Diabetes Registry. Diabetes care. Jun 11 2013.
  46. Liguori I, Russo G, Curcio F, et al. Depression and chronic heart failure in the elderly: an intriguing relationship. J Geriatr Cardiol. Jun 2018;15(6):451-459.
  47. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2013;62(16):e147-239.
  48. NHLBI. Sleep Apnea. Health topics. Accessed 02/07/19.
  49. Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proceedings of the American Thoracic Society. 2008;5(2):136-143.
  50. Costanzo MR. Mechanisms and Clinical Consequences of Untreated Central Sleep Apnea in Heart Failure. Journal of the American College of Cardiology. 2015;65(1):72.
  51. Khattak HK. Obstructive Sleep Apnea in Heart Failure: Review of Prevalence, Treatment with Continuous Positive Airway Pressure, and Prognosis. Texas Heart Institute journal. 2018;45(3):151-161.
  52. Gottlieb, D.J., Yenokyan, G., Newman, A.B., O'Connor, G.T., Punjabi, N.M., Quan, S.F., et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010;122(4):352-60.
  53. Drager LF, Polotsky VY, et al. Obstructive Sleep Apnea: An Emerging Risk Factor for Atherosclerosis. Chest. 2011;140:534-42.
  54. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive Sleep Apnea: The Most Common Secondary Cause of Hypertension Associated with Resistant Hypertension. Hypertension. 2011;58:811-17.
  55. Aronsohn RS, Whitmore H et al. Impact of Untreated Obstructive Sleep Apnea on Glucose control in Type 2 Diabetes. American Journal of Respiratory Critical Care, 2010; 181; 507-513.
  56. Nieto FJ, Peppard PE, Young T, et al. Sleep disordered breathing and cancer mortality: results from the Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med. 2012 May 20. [Epub ahead of print].
  57. Yaggi HK, Concato J. Obstructive Sleep Apnea as a Risk Factor for Stroke and Death. NEJM. 2005;353(19):2034-41.
  58. Page RL, O’Bryant CL, Cheng D, et al. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2016;134(6):e32-e69.
  59. Díez-López C, Lupón J, de Antonio M, et al. Hemoglobin Kinetics and Long-term Prognosis in Heart Failure. Revista Española de Cardiología (English Edition). 2016;69(09):820-826.
  60. Mbakwem A, Aina F, Amadi C. Depression in Patients with Heart Failure: Is Enough Being Done? Cardiac Failure Review. 2016;2(2).
  61. Mayo Clinic. High blood pressure (hypertension). Symptoms & causes. Last updated 5/12/2018. Accessed 3/5/2019.
  62. N.Y. Criteria Committee, N. Y. H. A. Diseases of the Heart and Blood Vessels. Nomenclature and Criteria for Diagnosis ... Sixth Edition. [With Illustrations.]. 1964.
  63. Jessup, M., Abraham, W. T., Casey, D. E.,  2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):1977–2016.
  64. Brozena, S. C., and Jessup, M. The new staging system for heart failure. What every primary care physician should know. Geriatrics. 2003;58(6):31–6–quiz38.
  65. Cardiology Review. ACC/AHA Heart Failure Classification. Accessed 3/5/2019.
  66. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European journal of heart failure. 2016;18(8):891-975.
  67. Association AH. Cardiomyopathy. 2016.
  68. Mangalat, D., Kalogeropoulos, A., Georgiopoulou, V., Stillman, A., Butler, J. Value of Cardiac CT in Patients With Heart Failure. Curr Cardiovasc Imaging Rep. 2009;2(6):410-417.
  69. Peterzan MA, Rider OJ, Anderson LJ. The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure. Cardiac failure review. 2016;2(2):115-122.
  70. Weber, M., Hamm, C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92(6):843-9.
  71. Di Angelantonio, E., Chowdhury, R., Sarwar, N.,  B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation. 2009;120(22):2177–87.
  72. Kim H-N, Januzzi JL. Natriuretic Peptide Testing in Heart Failure. Circulation. 2011;123(18):2015-2019.
  73. Gaggin HK, Januzzi JL. Cardiac Biomarkers and Heart Failure. Latest in Cardiology: Expert Analysis Accessed 02/11/2019.
  74. Göran Nilsson PH, John Ohrvik. How to live until 90 – Factors predicting survival in 75-year-olds from the general population. Healthy Aging Research. 2014;3.
  75. Nagarajan, V., Hernandez, A. V., and Tang, W. H. W. Prognostic value of cardiac troponin in chronic stable heart failure: a systematic review. Heart. 2012;98(24):1778–86.
  76. Nagarajan, V., and Tang, W. H. W. Biomarkers in advanced heart failure: diagnostic and therapeutic insights. Congest Heart Fail. 2011;17(4):169–74.
  77. Wang, M., Liao, Y. Value of quantitative analysis of serum cTnT in diagnosis of cardiac disease and myocardial injury. J Tongji Med Univ. 2000;20(1):53-4.
  78. Nishio, Y., Sato, Y., Taniguchi, R., Shizuta, S., Doi, T., Morimoto, T., Kimura, T., Kita, T. Cardiac troponin T vs other biochemical markers in patients with congestive heart failure. Circ J. 2007;71(5):631-5.
  79. McQueen, M. J., Kavsak, P. A., Xu, L., Shestakovska, O., and Yusuf, S. Predicting myocardial infarction and other serious cardiac outcomes using high-sensitivity cardiac troponin T in a high-risk stable population. Clin. Biochem. 2013;46(1-2):5–9.
  80. Evans JDW, Dobbin SJH, Pettit SJ, Di Angelantonio E, Willeit P. High-Sensitivity Cardiac Troponin and New-Onset Heart Failure: A Systematic Review and Meta-Analysis of 67,063 Patients With 4,165 Incident Heart Failure Events. JACC: Heart Failure. 2018;6(3):187-197.
  81. Magnussen C, Blankenberg S. Biomarkers for heart failure: small molecules with high clinical relevance. Journal of internal medicine. 2018;283(6):530-543.
  82. Nooralam Ansari* AH, Mohammad Owais. A study of inflammatory markers and their correlation with severity, in patients with chronic heart failure. Biomedical Research. 2012;23(3).
  83. McCarthy CP, Januzzi JL, Jr. Soluble ST2 in Heart Failure. Heart failure clinics. 2018;14(1):41-48.
  84. Gehlken C, Suthahar N, Meijers WC, de Boer RA. Galectin-3 in Heart Failure: An Update of the Last 3 Years. Heart failure clinics. 2018;14(1):75-92.
  85. van Kimmenade, R. R. J., and Januzzi, J. L. Emerging biomarkers in heart failure. Clin Chem. 2012;58(1):127–38.
  86. Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice. Circulation. Nov 15 2011;124(20):2253-2263.
  87. Gujja P, Rosing DR, Tripodi DJ, Shizukuda Y. Iron overload cardiomyopathy: better understanding of an increasing disorder. Journal of the American College of Cardiology. Sep 21 2010;56(13):1001-1012.
  88. Murphy CJ, Oudit GY. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. Journal of cardiac failure. Nov 2010;16(11):888-900.
  89. Ambrosy AP, Lewis GD, Malhotra R, et al. Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. Journal of cardiovascular medicine (Hagerstown, Md). 2018.
  90. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, . . . Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis. American heart journal. Apr 2013;165(4):575-582.e573.
  91. Comin-Colet J, Enjuanes C, Gonzalez G, Torrens A, Cladellas M, Merono O, . . . Bruguera J. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. European journal of heart failure. Jul 15 2013.
  92. Filippatos G, Farmakis D, Colet JC, Dickstein K, Luscher TF, Willenheimer R, . . . Anker SD. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. European journal of heart failure. Jul 18 2013.
  93. Kapoor M, Schleinitz MD, Gemignani A, Wu WC. Outcomes of patients with chronic heart failure and iron deficiency treated with intravenous iron: a meta-analysis. Cardiovascular & hematological disorders drug targets. Mar 1 2013;13(1):35-44.
  94. Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. European journal of heart failure. Apr 2012;14(4):423-429.
  95. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, . . . Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. European heart journal. Aug 2010;31(15):1872-1880.
  96. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Colvin MM, . . . Westlake C. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6).
  97. Westenbrink BD, Visser FW, Voors AA, Smilde TD, Lipsic E, Navis G, . . . van Veldhuisen DJ. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. European heart journal. Jan 2007;28(2):166-171.
  98. Shah R, Agarwal AK. Anemia associated with chronic heart failure: current concepts. Clinical interventions in aging. 2013;8:111-122.
  99. Pereira CA, Roscani MG, Zanati SG, Matsubara BB. Anemia, heart failure and evidence-based clinical management. Arquivos brasileiros de cardiologia. Jul 2013;101(1):87-92.
  100. Kilicgedik A, Dundar C, Tigen MK. Anemia in heart failure. Anadolu kardiyoloji dergisi: AKD = the Anatolian journal of cardiology. Feb 2012;12(1):65-70.
  101. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. Journal of the American College of Cardiology. 2013;62(16):1495.
  102. Izzo JL, Jr., Weir MR. Angiotensin-converting enzyme inhibitors. Journal of clinical hypertension (Greenwich, Conn.). Sep 2011;13(9):667-675.
  103. BHS. British and Irish Hypertension Society. Drug Classes: Angiotensin Converting Enzyme (ACE) Inhibitors. 12/2008. Accessed 11/3/2017.
  104. McMurray JJ, Pfeiffer MA. Goldman-Cecil Medicine, Twenty-Fifth Edition. Chapter 59: Heart Failure: Management and Prognosis; 305-320e1. Copyright 2016 by Saunders, an imprint of Elsevier, Inc. Accessed 11/3/2017.
  105. Taylor AA, Siragy H, Nesbitt S. Angiotensin receptor blockers: pharmacology, efficacy, and safety. Journal of clinical hypertension (Greenwich, Conn.). Sep 2011;13(9):677-686.
  106. Takagi H, Umemoto T. A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients. Journal of the American Society of Hypertension: JASH. 2014;8(8):578-592.
  107. AHA. American Heart Association. How do beta blocker drugs affect exercise? Copyright 2017b. Accessed 11/3/2017.
  108. Fisker FY, Grimm D, Wehland M. Third-generation beta-adrenoceptor antagonists in the treatment of hypertension and heart failure. Basic Clin Pharmacol Toxicol. Jul 2015;117(1):5-14.
  109. Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal. 2018;39(1):26-35.
  110. Preiss D, Campbell RT, Murray HM, et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J. 2015;36(24):1536-1546.
  111. Kaplinsky E. Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination. Journal of geriatric cardiology: JGC. Nov 2016;13(11):914-923.
  112. Wong PC, Guo J, Zhang A. The renal and cardiovascular effects of natriuretic peptides. Advances in physiology education. Jun 01 2017;41(2):179-185.
  113. Yandrapalli S, Aronow WS, Mondal P, Chabbott DR. The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan. Archives of medical science: AMS. Aug 2017;13(5):1207-1216.
  114. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019;380(6):539-548.
  115. King JB, Shah RU, Bress AP, Nelson RE, Bellows BK. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction. JACC. Heart failure. May 2016;4(5):392-402.
  116. Sehn E, McDonald T, Lindblad AJ. Sacubitril-valsartan: novel therapy for heart failure. Canadian family physician Medecin de famille canadien. Sep 2017;63(9):697.
  117. Marques da Silva P, Aguiar C. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure. Revista portuguesa de cardiologia: orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology: an official journal of the Portuguese Society of Cardiology. Sep 2017;36(9):655-668.
  118. Wilfried Mullens1, Kevin Damman3, Veli-Pekka Harjola4, Alexandre Mebazaa5,, Hans-Peter Brunner-La Rocca6 PM, 2, Jeffrey M. Testani7,, W.H. Wilson Tang8 FO, Patrick Rossignol10, Marco Metra11, Gerasimos Filippatos12, Petar M. Seferovic14, Frank Ruschitzka15,, Coats16 aAJ. The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2019.
  119. Rathnayake D, Sinclair R. Use of spironolactone in dermatology. Skinmed. Nov-Dec 2010;8(6):328-332; quiz 333.
  120. Booth RE, Johnson JP, Stockand JD. Aldosterone. Advances in physiology education. Dec 2002;26(1-4):8-20.
  121. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2014;370(15):1383-1392.
  122. Brown NJ. Eplerenone: cardiovascular protection. Circulation. 2003;107(19):2512-2518.
  123. Kapitanyan R, Su M. Drugs & Diseases page. Cardiac Glycoside Plant Poisoning: Practice Essentials. Last updated 3/28/2017. Accessed 11/3/2017.
  124. Ehle M, Patel C, Giugliano RP. Digoxin: clinical highlights: a review of digoxin and its use in contemporary medicine. Critical pathways in cardiology. Jun 2011;10(2):93-98.
  125. Gianluigi Savarese M, Robert P. Giugliano, MD, SM, Giuseppe M.C. Rosano, MD, PHD, John McMurray, MD, Giulia Magnani M, Gerasimos Filippatos, MD, PHD, Santo Dellegrottaglie, MD, PHD, Lars H. Lund, MD, PHD, Bruno Trimarco M, PHD, Pasquale Perrone-Filardi, MD, PHD. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure. JACC: Heart Failure. 2016;4.
  126. Savarese G, Giugliano RP, Rosano GMC, et al. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure. JACC: Heart Failure. 2016;4(11):870.
  127. Girerd N, Zannad F, Ferreira JP, Konstam MA, Alshalash S. Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges. European Heart Journal. 2016;37(31):2455-2464.
  128. Benjamin P. Geisler Md MJEL, MD, and Farrin A. Manian Md, MPH. Replacing warfarin with a NOAC in patients on chronic anticoagulation therapy. The Hospitalist. 2018.
  129. Bermingham M, Shanahan MK, O’Connell E, et al. Aspirin Use in Heart Failure. Circ Heart Fail. 2014;7(2):243-250.
  130. Pullicino PM, Thompson JLP, Sacco RL, et al. Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. Cerebrovascular diseases (Basel, Switzerland). 2013;36(1):74-78.
  131. Thomas I, EncisoSilva J, Schlueter M, Greenberg B. Anticoagulation Therapy and NOACs in Heart Failure. Handbook of experimental pharmacology. 2017;243:515-535.
  132. Homma S, Thompson JLP, Pullicino PM, et al. Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. N Engl J Med. 2012;366(20):1859-1869.
  133. Muller-Werdan U, Stockl G, Werdan K. Advances in the management of heart failure: the role of ivabradine. Vasc Health Risk Manag. 2016;12:453-470.
  134. Davis K, Dietrich E. Ivabradine (Corlanor) for Heart Failure. American family physician. Apr 15 2016;93(8):682-684.
  135. Alshammari TM. Ivabradine: Do the Benefits Outweigh the Risks? Journal of cardiovascular pharmacology and therapeutics. May 2017;22(3):210-218.
  136. Ambrosy AP, Pang PS, Gheorghiade M. Digoxin for Worsening Chronic Heart Failure. JACC: Heart Failure. 2016;4(5):365.
  137. Cocco G, Jerie P. Comparison between ivabradine and low-dose digoxin in the therapy of diastolic heart failure with preserved left ventricular systolic function. Clinics and practice. 2013;3(2):e29-e29.
  138. Mayo Clinic. Ventricular assist device (VAD). Last updated 1/16/2019. Accessed 3/6/2019.
  139. Marrouche NF, Brachmann J, Andresen D, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018;379(5):492.
  140. Cleveland JC, Jr., Naftel DC, Reece TB, et al. Survival after biventricular assist device implantation: an analysis of the Interagency Registry for Mechanically Assisted Circulatory Support database. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2011;30(8):862-869.
  141. Givertz MM, Stevenson LW, Costanzo MR, et al. Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. Oct 10 2017;70(15):1875-1886.
  142. Adler ED, Goldfinger JZ, Kalman J, Park ME, Meier DE. Palliative Care in the Treatment of Advanced Heart Failure. Circulation. 2009;120(25):2597-2606.
  143. AHA. American Heart Association. Conditions: Advanced Heart Failure. Last updated 5/9/2017a. Accessed 11/3/2017.
  144. Vrtovec B, Poglajen G, Haddad F. Stem cell therapy in patients with heart failure. Methodist Debakey Cardiovasc J. Jan-Mar 2013;9(1):6-10.
  145. Singh A, Singh A, Sen D. Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010-2015). Stem Cell Res Ther. Jun 4 2016;7(1):82.
  146. NLM. U.S. National Library of Medicine. Stem Cells. Last updated 9/16/2016. Accessed 9/29/2016.
  147. Katarzyna R. Adult Stem Cell Therapy for Cardiac Repair in Patients After Acute Myocardial Infarction Leading to Ischemic Heart Failure: An Overview of Evidence from the Recent Clinical Trials. Curr Cardiol Rev. 2017;13(3):223-231.
  148. Wernly B, Mirna M, Rezar R, et al. Regenerative Cardiovascular Therapies: Stem Cells and Beyond. Int J Mol Sci. Mar 21 2019;20(6).
  149. Yun CW, Lee SH. Enhancement of Functionality and Therapeutic Efficacy of Cell-Based Therapy Using Mesenchymal Stem Cells for Cardiovascular Disease. Int J Mol Sci. Feb 24 2019;20(4).
  150. Fisher SA, Doree C, Mathur A, Taggart DP, Martin-Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev. Dec 24 2016;12:Cd007888.
  151. Nguyen PK, Rhee JW, Wu JC. Adult Stem Cell Therapy and Heart Failure, 2000 to 2016: A Systematic Review. JAMA Cardiol. Oct 1 2016;1(7):831-841.
  152. Yau TM, Pagani FD, Mancini DM, et al. Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial. Jama. Mar 26 2019;321(12):1176-1186.
  153. Bartunek J, Terzic A, Davison BA, et al. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur Heart J. Mar 1 2017;38(9):648-660.
  154. Wernly B, Goncalves I, Kiss A, et al. Differences in Stem Cell Processing Lead to Distinct Secretomes Secretion-Implications for Differential Results of Previous Clinical Trials of Stem Cell Therapy for Myocardial Infarction. Biotechnol J. Sep 2017;12(9).
  155. Luscher TF. Back to square one. Eur Heart J. Apr 1 2019;40(13):1031-1033.
  156. Kalicinska E, Wojtas K, Majda J, Doehner W, Haehling SV, Banasiak W, . . . Jankowska EA. Anabolic deficiencies in men with systolic heart failure: do co-morbidities and therapies really contribute significantly? The aging male: the official journal of the International Society for the Study of the Aging Male. Jun 26 2013.
  157. Tirabassi G, Gioia A, Giovannini L, Boscaro M, Corona G, Carpi A, . . . Balercia G. Testosterone and cardiovascular risk. Internal and emergency medicine. Apr 2013;8 Suppl 1:S65-69.
  158. Volterrani, M., Rosano, G., and Iellamo, F. Testosterone and heart failure. Endocrine. 2012;42(2):272–7.
  159. Aukrust, P., Ueland, T., Gullestad, L., and Yndestad, A. Testosterone: a novel therapeutic approach in chronic heart failure? J Am Coll Cardiol. 2009;54(10):928–9.
  160. Giagulli VA, Guastamacchia E, De Pergola G, Iacoviello M, Triggiani V. Testosterone deficiency in male: a risk factor for heart failure. Endocrine, metabolic & immune disorders drug targets. 2013;13(1):92-99.
  161. Han Y, Sun W, Sun G, et al. A 3-year observation of testosterone deficiency in Chinese patients with chronic heart failure. Oncotarget. 2017;8(45):79835-79842.
  162. Wang W, Jiang T, Li C, et al. Will testosterone replacement therapy become a new treatment of chronic heart failure? A review based on 8 clinical trials. Journal of thoracic disease. 2016;8(5):E269-277.
  163. Dos Santos MR, Sayegh AL, Bacurau AV, et al. Effect of Exercise Training and Testosterone Replacement on Skeletal Muscle Wasting in Patients With Heart Failure With Testosterone Deficiency. Mayo Clinic proceedings. 2016;91(5):575-586.
  164. Iellamo, F., Volterrani, M., Caminiti, G., et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol. 2010;56(16):1310–6.
  165. Kloner RA. Testosterone and Cardiovascular Disease. J Am Coll Cardiol. 2016;67(5):545-557.
  166. Bibevski, S., Dunlap, M.E. Evidence for impaired vagus nerve activity in heart failure. Heart Fail Rev. 2011;16(2):129-35.
  167. De Ferrari, G. M., Crijns, H. J. G. M., Borggrefe, M. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. European Heart Journal. 2011;32(7):847–55.
  168. Sabbah, H.N. Electrical vagus nerve stimulation for the treatment of chronic heart failure. Cleve Clin J Med. 2011;78 Suppl 1:S24-9.
  169. Gold MR, Van Veldhuisen DJ, Hauptman PJ, et al. Vagus Nerve Stimulation for the Treatment of Heart Failure. Journal of the American College of Cardiology. 2016;68(2):149.
  170. Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovascular research. Feb 15 2009;81(3):412-419.
  171. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiological reviews. Jan 2010;90(1):207-258.
  172. Lopatin YM. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. International journal of cardiology. 2016;203:909-915.
  173. Grajek S, Michalak M. The effect of trimetazidine added to pharmacological treatment on all-cause mortality in patients with systolic heart failure. Cardiology. 2015;131(1):22-29.
  174. Zhou X, Chen J. Is treatment with trimetazidine beneficial in patients with chronic heart failure? PLoS One. 2014;9(5):e94660.
  175. Zhang L, Lu Y, Jiang H, Zhang L, Sun A, Zou Y, Ge J. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. Journal of the American College of Cardiology. Mar 6 2012;59(10):913-922.
  176. Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart (British Cardiac Society). Feb 2011;97(4):278-286.
  177. Winter JL, Castro PF, Quintana JC, et al. Effects of trimetazidine in nonischemic heart failure: a randomized study. Journal of cardiac failure. 2014;20(3):149-154.
  178. Brodbin P, O'Connor CA. Trimetazidine in the treatment of angina pectoris. The British journal of clinical practice. Sep 1968;22(9):395-396.
  179. Masmoudi K, Masson H, Gras V, Andrejak M. Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases. Fundamental & clinical pharmacology. Apr 2012;26(2):198-203.
  180. Montastruc JL, Sommet A, Olivier P, Bagheri H, Gony M, Lapeyre-Mestre M, . . . Rascol O. [Drugs, Parkinson's disease and parkinsonian syndroms: recent advances in pharmacovigilance]. Therapie. Jan-Feb 2006;61(1):29-38.
  181. Syvannarath V, Delbosc S, Escoubet B, et al. Treatment with a CD31 agonist peptide improves the outcome of experimental heart failure with either reduced or preserved ejection fraction. Archives of Cardiovascular Diseases Supplements. 2018;10(2):197-198.
  182. Costanzo MR. Ultrafiltration In The Management Of Heart Failure. US Cardiology Review. 2008;5(1):66-69.
  183. Djousse L, Gaziano JM. Alcohol consumption and heart failure: a systematic review. Current atherosclerosis reports. Apr 2008;10(2):117-120.
  184. Piano MR. Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology. Chest. May 2002;121(5):1638-1650.
  185. CDC (Centers for Disease Control and Prevention) (US); National Center for Chronic Disease Prevention and Health Promotion (US); Office on Smoking and Health (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2010. 6, Cardiovascular Diseases.
  186. Clair, C., Rigotti, N.A., Porneala, B., Fox, C.S., D'Agostino, R.B., Pencina, M.J., Meigs, J.B. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA. 2013;309(10):1014-21.
  187. Sacks, F., Svetkey, L., Vollmer, W., and Appel, L. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001; 344(1):3-10.
  188. Tejada, T., Fornoni, A., Lenz, O., Materson, B.J. Nonpharmacologic therapy for hypertension: does it really work?. Curr Cardiol Rep. 2006;8(6):418-24.
  189. Kerley CP. Dietary patterns and components to prevent and treat heart failure: a comprehensive review of human studies. Nutr Res Rev. Aug 16 2018:1-27.
  190. Rifai L, Silver MA. A Review of the DASH Diet as an Optimal Dietary Plan for Symptomatic Heart Failure. Prog Cardiovasc Dis. Mar-Apr 2016;58(5):548-554.
  191. Brooks M. Benefit of Salt Restriction in Heart Failure Uncertain. Medscape Medical News Accessed 02/12/2019.
  192. Doukky R, Avery E, Mangla A, et al. Impact of Dietary Sodium Restriction on Heart Failure Outcomes. JACC. Heart failure. 2016;4(1):24-35.
  193. Hummel SL, Konerman MC. Dietary Sodium Restriction in Heart Failure: A Recommendation Worth its Salt?∗. JACC: Heart Failure. 2016/01/01/ 2016;4(1):36-38.
  194. Yancy CW. The Uncertainty of Sodium Restriction in Heart Failure: We Can Do Better Than This∗. JACC: Heart Failure. 2016/01/01/ 2016;4(1):39-41.
  195. Kerley CP. A Review of Plant-based Diets to Prevent and Treat Heart Failure. Card Fail Rev. May 2018;4(1):54-61.
  196. Dragan S, Buleu F, Christodorescu R, et al. Benefits of multiple micronutrient supplementation in heart failure: A comprehensive review. Critical reviews in food science and nutrition. 2018:1-17.
  197. Lennie Terry A, Andreae C, Rayens Mary K, et al. Micronutrient Deficiency Independently Predicts Time to Event in Patients With Heart Failure. Journal of the American Heart Association. 2018;7(17):e007251.
  198. Ceremuzyński, L., Gebalska, J., Wolk, R., and Makowska, E. Hypomagnesemia in heart failure with ventricular arrhythmias. Beneficial effects of magnesium supplementation. Acta Med Scand. 2000;247(1):78–86.
  199. Fang. Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality: a dose–response meta-analysis of prospective cohort studies. BMC Med. 2016;14(1):210.
  200. Azizi-Namini, P., Ahmed, M., Yan, A. T., and Keith, M. The role of B vitamins in the management of heart failure. Nutr Clin Pract. 2012;27(3):363–74.
  201. Krim, S. R., Campbell, P., Lavie, C. J., and Ventura, H. Micronutrients in chronic heart failure. Curr Heart Fail Rep. 2013;10(1):46–53.
  202. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. Aug 2016;18(8):891-975.
  203. American Heart Association. Cardiac Rehab for Heart Failure. Health Topics Accessed 02/15/2019.
  204. Piepoli MF, Conraads V, Corrà U, et al. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail. 2011;13(4):347-357.
  205. Downing, J., and Balady, G. J. The role of exercise training in heart failure. J Am Coll Cardiol. 2011;58(6):561–9.
  206. Ansley, D. M., and Wang, B. Oxidative stress and myocardial injury in the diabetic heart. J. Pathol. 2013;229(2):232–41.
  207. Papanas, N., Maltezos, E., and Mikhailidis, D. P. Metformin and heart failure: never say never again. Expert Opin Pharmacother. 2012;13(1):1–8.
  208. Facila L, Fabregat-Andres O, Bertomeu V, et al. Metformin and risk of long-term mortality following an admission for acute heart failure. J Cardiovasc Med (Hagerstown). Feb 2017;18(2):69-73.
  209. Martens P, Janssens J, Ramaekers J, Dupont M, Mullens W. Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. Acta Cardiol. Feb 8 2019:1-7.
  210. Saad M, Gomceli U, Ravi P, Lacoste AG, Shah N, Vittorio TJ. The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition. Drugs Context. 2018;7:212549.
  211. Association AH. Stress and Heart Health. 2014.
  212. Vongmany J, Hickman LD, Lewis J, Newton PJ, Phillips JL. Anxiety in chronic heart failure and the risk of increased hospitalisations and mortality: A systematic review. European journal of cardiovascular nursing: journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology. 2016;15(7):478-485.
  213. Levine GN, Lange RA, Bairey‐Merz CN, et al. Meditation and Cardiovascular Risk Reduction: A Scientific Statement From the American Heart Association. J Am Heart Assoc. 2017;6(10):e002218.
  214. Aggarwal M, Bozkurt B, Panjrath G, et al. Lifestyle Modifications for Preventing and Treating Heart Failure. Journal of the American College of Cardiology. 2018;72(19):2391.
  215. Rosenfeldt, F. L., Haas, S. J., Krum, H. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. 2007;21(4):297–306.
  216. Shimizu M. Low circulating coenzyme Q10 during acute phase is associated with inflammation, malnutrition, and in-hospital mortality in patients admitted to the coronary care unit. Heart and vessels. 2017;32(6):668-673.
  217. Lei L. Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials. BMC cardiovascular disorders. 2017;17(1):196-196.
  218. Jafari M, Mousavi SM, Asgharzadeh A, Yazdani N. Coenzyme Q10 in the treatment of heart failure: A systematic review of systematic reviews. Indian Heart Journal. 2018;70:S111-S117.
  219. Rosenfeldt F, Hilton D, Pepe S, Krum H. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. BioFactors (Oxford, England). 2003;18(1-4):91-100.
  220. Molyneux SL, Florkowski CM, George PM, Pilbrow AP, Frampton CM, Lever M, Richards AM. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. Journal of the American College of Cardiology. Oct 28 2008;52(18):1435-1441.
  221. Soja, A. M., and Mortensen, S. A. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol. Aspects Med. 1997;18 Suppl:S159–68.
  222. Sander, S., Coleman, C. I., Patel, A. A., Kluger, J., and White, C. M. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J. Card. Fail. 2006;12(6):464–72.
  223. Fotino, A. D., Thompson-Paul, A. M., and Bazzano, L. A. Effect of coenzyme Q₁₀ supplementation on heart failure: a meta-analysis. American Journal of Clinical Nutrition. 2013;97(2):268–75.
  224. Belcaro G, Cesarone MR, Dugall M, et al. Investigation of Pycnogenol(R) in combination with coenzymeQ10 in heart failure patients (NYHA II/III). Panminerva medica. 2010;52(2 Suppl 1):21-25.
  225. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, . . . McCullough PA. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. The New England journal of medicine. Jul 18 2002;347(3):161-167.
  226. Rigelsky JM, Sweet BV. Hawthorn: pharmacology and therapeutic uses. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists. Mar 1 2002;59(5):417-422.
  227. Urbonaviciute A, Jakstas V, Kornysova O, Janulis V, Maruska A. Capillary electrophoretic analysis of flavonoids in single-styled hawthorn (Crataegus monogyna Jacq.) ethanolic extracts. Journal of chromatography. A. Apr 21 2006;1112(1-2):339-344.
  228. Yang B, Liu P. Composition and health effects of phenolic compounds in hawthorn (Crataegus spp.) of different origins. Journal of the science of food and agriculture. Jun 2012;92(8):1578-1590.
  229. Schröder, D., Weiser, M., Klein, P. Efficacy of a homeopathic Crataegus preparation compared with usual therapy for mild (NYHA II) cardiac insufficiency: results of an observational cohort study. Eur J Heart Fail. 2003;5(3):319-26.
  230. Furey, A., and Tassell, M. Towards a systematic scientific approach in the assessment of efficacy of an herbal preparation: Hawthorn (Crataegus spp.). European Journal of Heart Failure. 2008;10(12):1153–7.
  231. Koch, E., and Malek, F. A. Standardized extracts from hawthorn leaves and flowers in the treatment of cardiovascular disorders--preclinical and clinical studies. Planta Med. 2011;77(11):1123–8.
  232. Cicero AFG, Colletti A. Nutraceuticals and Dietary Supplements to Improve Quality of Life and Outcomes in Heart Failure Patients. Current pharmaceutical design. 2017;23(8):1265-1272.
  233. Holubarsch CJF, Colucci WS, Meinertz T, et al. Survival and Pronosis: Investigation of Crataegus Extract WS 1442 in congestive heart failure (SPICE) – rationale, study design and study protocol. European Journal of Heart Failure. 2000;431-37.
  234. Holubarsch, C. J. F., Colucci, W. S., Meinertz, T., Gaus, W., Tendera, M., Survival and Prognosis: Investigation of Crataegus Extract WS 1442 in CHF (SPICE) trial study group. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. Eur. J. Heart Fail. 2008;10(12):1255–63.
  235. Zick, S. M., Vautaw, B. M., Gillespie, B., and Aaronson, K. D. Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial. Eur. J. Heart Fail. 2009;11(10):990–9.
  236. Rucker, R., Chowanadisai, W., and Nakano, M. Potential physiological importance of pyrroloquinoline quinone. Altern Med Rev. 2009;14(3):268–77.
  237. Hamilton DJ. Mechanisms of disease: is mitochondrial function altered in heart failure? Methodist DeBakey cardiovascular journal. Jan-Mar 2013;9(1):44-48.
  238. Nehra. Nanocurcumin–pyrroloquinoline formulation prevents hypertrophy–induced pathological damage by relieving mitochondrial stress in cardiomyocytes under hypoxic conditions. Experimental & Molecular Medicine. 2017;49.
  239. Zhu, B.-Q., Simonis, U., Cecchini, G., et al. Comparison of pyrroloquinoline quinone and/or metoprolol on myocardial infarct size and mitochondrial damage in a rat model of ischemia/reperfusion injury. J. Cardiovasc. Pharmacol. Ther. 2006;11(2):119–28.
  240. Zhu, B.-Q., Zhou, H.-Z., Teerlink, J. R., and Karliner, J. S. Pyrroloquinoline quinone (PQQ) decreases myocardial infarct size and improves cardiac function in rat models of ischemia and ischemia/reperfusion. Cardiovasc Drugs Ther. 2004;18(6):421–31.
  241. Siscovick. Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease. Circulation. 2017;135.
  242. Marik, P. E., and Varon, J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol. 2009;32(7):365–72.
  243. Geleijnse, J. M., Giltay, E. J., Grobbee, D. E., Donders, A. R. T., and Kok, F. J. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J. Hypertens. 2002;20(8):1493–9.
  244. Wang C, Xiong B, Huang J. The Role of Omega-3 Polyunsaturated Fatty Acids in Heart Failure: A Meta-Analysis of Randomised Controlled Trials. Nutrients. 2017;9(1):18.
  245. Xin, W., Wei, W., and Li, X. Effects of fish oil supplementation on cardiac function in chronic heart failure: a meta-analysis of randomised controlled trials. Heart. 2012;98(22):1620–5.
  246. Mehra, M. R., Lavie, C. J., Ventura, H. O., and Milani, R. V. Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. J. Heart Lung Transplant. 2006;25(7):834–8.
  247. Jiang W, Whellan DJ, Adams KF, et al. Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial. JACC Heart Fail. Oct 2018;6(10):833-843.
  248. Moreira da Silva Guimaraes S, de Souza Cruz WM, de Souza Weigert G, et al. Decompensated Chronic Heart Failure Reduces Plasma L-carnitine. Archives of medical research. 2018;49(4):278-281.
  249. Song X, Qu H, Yang Z, Rong J, Cai W, Zhou H. Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials. Biomed Res Int. 2017;2017:6274854.
  250. Wang ZY, Liu YY, Liu GH, Lu HB, Mao CY. l-Carnitine and heart disease. Life sciences. 2018;194:88-97.
  251. Soukoulis, V., Dihu, J. B., Sole, M. Micronutrient deficiencies an unmet need in heart failure. J Am Coll Cardiol. 2009;54(18):1660–73.
  252. Anand, I., Chandrashekhan, Y., De Giuli, F. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther. 1998;12(3):291–9.
  253. Mancini, M., Rengo, F., Lingetti, M., Sorrentino, G. P., and Nolfe, G. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforschung. 1992;42(9):1101–4.
  254. Rizos, I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am. Heart J. 2000; 139(2 Pt 3):S120-3.
  255. Glickman-Simon, R., and Ehrlich, A. Leeches, creatine, xylitol, spinal manipulation, acupuncture. Explore (NY). 2012;8(3):206–9.
  256. Horjus, D. L., Oudman, I., van Montfrans, G. A., and Brewster, L. M. Creatine and creatine analogues in hypertension and cardiovascular disease. Cochrane Database Syst Rev. 2011;(11):CD005184.
  257. Hemati F, Rahmani A, Asadollahi K, Soleimannejad K, Khalighi Z. Effects of Complementary Creatine Monohydrate and Physical Training on Inflammatory and Endothelial Dysfunction Markers Among Heart Failure Patients. Asian journal of sports medicine. 2016;7(1):e28578-e28578.
  258. Ahmadian M, Dabidi Roshan V, Ashourpore E. Taurine Supplementation Improves Functional Capacity, Myocardial Oxygen Consumption, and Electrical Activity in Heart Failure. Journal of dietary supplements. 2017;14(4):422-432.
  259. Ahmadian M, Roshan VD, Aslani E, Stannard SR. Taurine supplementation has anti-atherogenic and anti-inflammatory effects before and after incremental exercise in heart failure. Ther Adv Cardiovasc Dis. 2017;11(7):185-194.
  260. Beyranvand, M. R., Khalafi, M. K., Roshan, V. D., Choobineh, S., Parsa, S. A., and Piranfar, M. A. Effect of taurine supplementation on exercise capacity of patients with heart failure. J Cardiol. 2011;57(3):333–7.
  261. Azuma, J., Sawamura, A., and Awata, N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn. Circ. J. 1992;56(1):95–9.
  262. Shecterle, L. M., Wagner, S., and St Cyr, J. A. A sugar for congestive heart failure patients. Ther Adv Cardiovasc Dis. 2011;5(2):95–7.
  263. Bayram M, St. Cyr JA, Abraham WT. d-Ribose aids heart failure patients with preserved ejection fraction and diastolic dysfunction: a pilot study. Ther Adv Cardiovasc Dis. 2015;9(3):56-65.
  264. Omran H, Illien S, MacCarter D, et al. D-Ribose improves diastolic function and quality of life in congestive heart failure patients: a prospective feasibility study. The European Journal of Heart Failure. 2003; 5: 615-19.
  265. Vijay, N., MacCarter, D., Shecterle, L. M., and St Cyr, J. A. D-ribose benefits heart failure patients. J Med Food. 2008;11(1):199–200.
  266. Omran, H., McCarter, D., St Cyr, J., and Lüderitz, B. D-ribose aids congestive heart failure patients. Exp Clin Cardiol. 2004;9(2):117–8.
  267. AMR. Terminalia arjuna. Alternative medicine review: a journal of clinical therapeutic. Dec 1999;4(6):436-437.
  268. Dwivedi S. Terminalia arjuna Wight & Arn.--a useful drug for cardiovascular disorders. Journal of ethnopharmacology. Nov 1 2007;114(2):114-129.
  269. Amalraj A, Gopi S. Medicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: A review. Journal of Traditional and Complementary Medicine. 2017;7(1):65-78.
  270. Munasinghe TCJ, Seneviratne CK, Thabrew MI, Abeysekera AM. Antiradical and antilipoperoxidative effects of some plant extracts used by Sri Lankan traditional medical practitioners for cardioprotection. Phytotherapy research: PTR. Sep 2001;15(6):519-523.
  271. Gauthaman K, Maulik M, Kumari R, Manchanda SC, Dinda AK, Maulik SK. Effect of chronic treatment with bark of Terminalia arjuna: a study on the isolated ischemic-reperfused rat heart. Journal of ethnopharmacology. May 2001;75(2-3):197-201.
  272. Karthikeyan K, Bai BR, Gauthaman K, Sathish KS, Devaraj SN. Cardioprotective effect of the alcoholic extract of Terminalia arjuna bark in an in vivo model of myocardial ischemic reperfusion injury. Life sciences. Oct 10 2003;73(21):2727-2739.
  273. Ram A, Lauria P, Gupta R, Kumar P, Sharma VN. Hypocholesterolaemic effects of Terminalia arjuna tree bark. Journal of ethnopharmacology. Feb 1997;55(3):165-169.
  274. Maulik SK, Katiyar CK. Terminalia arjuna in cardiovascular diseases: making the transition from traditional to modern medicine in India. Current pharmaceutical biotechnology. Dec 2010;11(8):855-860.
  275. Oberoi L, Akiyama T, Lee KH, Liu SJ. The aqueous extract, not organic extracts, of Terminalia arjuna bark exerts cardiotonic effect on adult ventricular myocytes. Phytomedicine: international journal of phytotherapy and phytopharmacology. Feb 15 2011;18(4):259-265.
  276. Shaila HP, Udupa SL, Udupa AL. Hypolipidemic activity of three indigenous drugs in experimentally induced atherosclerosis. International journal of cardiology. Dec 1 1998;67(2):119-124.
  277. Subramaniam S, Ramachandran S, Uthrapathi S, Gnamanickam VR, Dubey GP. Anti-hyperlipidemic and antioxidant potential of different fractions of Terminalia arjuna Roxb. bark against PX- 407 induced hyperlipidemia. Indian journal of experimental biology. Apr 2011;49(4):282-288.
  278. Subramaniam S, Subramaniam R, Rajapandian S, Uthrapathi S, Gnanamanickam VR, Dubey GP. Anti-Atherogenic Activity of Ethanolic Fraction of Terminalia arjuna Bark on Hypercholesterolemic Rabbits. Evidence-based complementary and alternative medicine: eCAM. 2011;2011:487916.
  279. Gupta R, Singhal S, Goyle A, Sharma VN. Antioxidant and hypocholesterolaemic effects of Terminalia arjuna tree-bark powder: a randomised placebo-controlled trial. The Journal of the Association of Physicians of India. Feb 2001;49:231-235.
  280. Bharani A, Ahirwar LK, Jain N. Terminalia arjuna reverses impaired endothelial function in chronic smokers. Indian heart journal. Mar-Apr 2004;56(2):123-128.
  281. Beveridge, L. A., and Witham, M. D. Vitamin D and the cardiovascular system. Osteoporos Int. 2013; 24(8):167-80.
  282. Catarina Magalhães Porto VDLS, João Soares Brito da Luz, Brivaldo Markman Filho,and Vera Magalhães da Silveira. Association between vitamin D deficiency and heart failure risk in the elderly. ESC Heart Failure. 2018;5:63-74.
  283. Liu, L. C. Y., Voors, A. A., van Veldhuisen, D. J., et al. Vitamin D status and outcomes in heart failure patients. Eur. J. Heart Fail. 2011;13(6):619–25.
  284. Pourdjabbar, A., Dwivedi, G., and Haddad, H. The role of vitamin D in chronic heart failure. Curr. Opin. Cardiol. 2013;28(2):216–22.
  285. Moretti HD, Colucci VJ, Berry BDJBCD. Vitamin D3 repletion versus placebo as adjunctive treatment of heart failure patient quality of life and hormonal indices: a randomized, double-blind, placebo-controlled trial. BMC Cardiovasc Disord. 2017;17(1):274.
  286. Bae, S., Singh, S. S., Yu, H., Lee, J. Y., Cho, B. R., and Kang, P. M. Vitamin D signaling pathway plays an important role in the development of heart failure after myocardial infarction. J Appl Physiol. 2013;114(8):979–87.
  287. Amin, A., Minaee, S., Chitsazan, M., Naderi, N., Taghavi, S., and Ardeshiri, M. Can Vitamin D Supplementation Improve the Severity of Congestive Heart Failure? Congest Heart Fail. 2013; Mar 21. doi: 10.1111/chf.12026. [Epub ahead of print].
  288. Witham, M. D., Crighton, L. J., Gillespie, N. D., Struthers, A. D., and McMurdo, M. E. T. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circ Heart Fail. 2010;3(2):195–201.
  289. Schleithoff, S. S., Zittermann, A., Tenderich, G., Berthold, H. K., Stehle, P., and Koerfer, R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83(4):754–9.
  290. Witham, M. D., Nadir, M. A., and Struthers, A. D. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J. Hypertens. 2009;27(10):1948–54.
  291. Riba. Cardioprotective Effect of Resveratrol in a Postinfarction Heart Failure Model. Oxidative Medicine and Cellular Longevity. 2017.
  292. Berman. The therapeutic potential of resveratrol: a review of clinical trials. npj Precision Oncology. 2017.
  293. Lymbury, R.S., Marino, M.J., Perkins, A.V. Effect of dietary selenium on the progression of heart failure in the ageing spontaneously hypertensive rat. Mol Nutr Food Res. 2010;54(10):1436-44.
  294. McKeag, N.A., McKinley, M.C., Woodside, J.V., Harbinson, M.T., McKeown, P.P. The role of micronutrients in heart failure. J Acad Nutr Diet. 2012;112(6):870-86.
  295. Saliba, W., El Fakih, R., Shaheen, W. Heart failure secondary to selenium deficiency, reversible after supplementation. Int J Cardiol. 2010;141(2):e26-7.
  296. Raygan F, Behnejad M, Ostadmohammadi V, et al. Selenium supplementation lowers insulin resistance and markers of cardio-metabolic risk in patients with congestive heart failure: a randomised, double-blind, placebo-controlled trial. British Journal of Nutrition. 2018;120(1):33-40.
  297. DiNicolantonio JJ, Liu J, O’Keefe JH. Magnesium for the prevention and treatment of cardiovascular disease. Open Heart. 2018;5(2):e000775.
  298. Supplements NIoHOoD. Magnesium: Fact Sheet for Professionals. 2018.
  299. Rosique-Esteban N, Guasch-Ferré M, Hernández-Alonso P, Salas-Salvadó J. Dietary Magnesium and Cardiovascular Disease: A Review with Emphasis in Epidemiological Studies. Nutrients. 2018;10(2):168.
  300. Almoznino-Sarafian D, Sarafian G, Berman S, Shteinshnaider M, Tzur I, Cohen N, Gorelik O. Magnesium administration may improve heart rate variability in patients with heart failure. Nutrition, metabolism, and cardiovascular diseases: NMCD. Nov 2009;19(9):641-645.
  301. Fuentes JC, Salmon AA, Silver MA. Acute and chronic oral magnesium supplementation: effects on endothelial function, exercise capacity, and quality of life in patients with symptomatic heart failure. Congestive heart failure (Greenwich, Conn.). Jan-Feb 2006;12(1):9-13.
  302. Stepura OB, Martynow AI. Magnesium orotate in severe congestive heart failure (MACH). International journal of cardiology. Jan 9 2009;131(2):293-295.
  303. FDA. U.S. Food and Drug Administration. FDA approves new device for treating moderate to severe chronic heart failure in patients. In: United States Dept of Health and Human Services. 3/21/2019. Accessed 3/27/2019.
  304. Abraham WT, Kuck KH, Goldsmith RL, et al. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. JACC Heart failure. 2018;6(10):874-883.
  305. Anker SD, Borggrefe M, Neuser H, et al. Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction. European journal of heart failure. 2019.
  306. Kuschyk J, Roeger S, Schneider R, et al. Efficacy and survival in patients with cardiac contractility modulation: long-term single center experience in 81 patients. Int J Cardiol. 2015;183:76-81.
  307. Kloppe A, Lawo T, Mijic D, Schiedat F, Muegge A, Lemke B. Long-term survival with Cardiac Contractility Modulation in patients with NYHA II or III symptoms and normal QRS duration. Int J Cardiol. 2016;209:291-295.
  308. Impulse Dynamics. Implantation. Copyright 2019. Accessed 3/27/2019.
  309. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. Mar 17 2000;86(5):580-588.
  310. Zheng S, Du Y, Peng Q, Fan X, Li J, Chen M. Trimetazidine Protects Against Atherosclerosis by Changing Energy Charge and Oxidative Stress. Medical science monitor : international medical journal of experimental and clinical research. 2018;24:8459-8468.
  311. Liu X, Gai Y, Liu F, et al. Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway. Cardiovasc Res. Oct 1 2010;88(1):150-158.
  312. Wen J, Ma X, Zhang L, et al. Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy: A systematic review and meta-analysis. Medicine (Baltimore). Dec 2018;97(51):e13580.
  313. Coats CJ, Pavlou M, Watkinson OT, et al. Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. JAMA Cardiol. Feb 6 2019.
  314. Hoque MH, Kabir FI, Arzu J, et al. Comparison between Glyceryl Trinitrate and Trimetazidine in Ischaemic Cardiomyopathy Patients. Mymensingh Med J. Jan 2019;28(1):114-119.
  315. Chrusciel P, Rysz J, Banach M. Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease. Drugs. Jun 2014;74(9):971-980.
  316. Kwon J, Yu YM, Kim S, Jeong KH, Lee E. Association between Trimetazidine and Parkinsonism: A Population-Based Study. Neuroepidemiology. Mar 4 2019;52(3-4):220-226.
  317. Pinter D, Kovacs M, Harmat M, Juhasz A, Janszky J, Kovacs N. Trimetazidine and parkinsonism: A prospective study. Parkinsonism Relat Disord. Jan 4 2019.
  318. Trimetazidine clinical trials, recruiting or not yet recruiting. 2019. Accessed Apr. 16, 2019.
  319. Guarini G, Huqi A, Morrone D, Capozza PFG, Marzilli M. Trimetazidine and Other Metabolic Modifiers. Eur Cardiol. Dec 2018;13(2):104-111.
  320. Zou H, Zhu XX, Ding YH, et al. Trimetazidine in conditions other than coronary disease, old drug, new tricks? Int J Cardiol. May 1 2017;234:1-6.